Diagnostic management of inaugurable metastases;Prise en charge diagnostique des métastases inaugurables

Presse Medicale

Volumn 32, Issue 21, 2003, Pages 990-996

  Penel, Nicolas ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PROSTATE SPECIFIC ANTIGEN;

AXILLARY LYMPH NODE; BREAST CANCER; CARCINOMA; CARCINOMA OF UNKNOWN PRIMARY SITE; CARCINOMATOSIS; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAMMOGRAPHY; MEDIAN LINE SYNDROME; METASTASIS; OCCULT CANCER; POSITRON EMISSION TOMOGRAPHY; PRIMARY PAPILLARY PERITONEAL CARCINOMATOSIS; PROGNOSIS; REVIEW; THORAX RADIOGRAPHY;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; CARCINOMA; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROSTATE-SPECIFIC ANTIGEN; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038613755     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Bugat R, Bataillard A, Lesimple T et al. Standard, Options et recommandations 2002 pour la prise en charge des patients atteints de carcinomes de site primitif inconnu (rapport abrégé). Bull Cancer 2002; 89: 869-75
2. Oen AL, De Boer MF, Hop WC, Kneght P. Cervical metastasis from the unknown primary tumor. Eur Arch Otolaryngol 1995; 252: 222-8.
3. Jungehulsing M, Scheidhauer K, Damm M. et al. 2 [F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sentitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head and Neck Surg 2000; 123: 294-301.
4. Mendenhall WM, Mancuso AA, Amdur RJ, Stringer SP, Villaret D, Cassisi NJ. Squamous cell carcinoma to the neck from an unknown head and neck primary site. Am J Otolaryngol 2001; 22: 261-7.
5. Randall DA, Johnstone PA, Foss RD, Martin PJ. Tonsillectomy in diagnosis of the unknown primary tumor of head and neck. Otolaryngol Head Neck Surg 2000; 122: 52-5
6. Eschwege F, de Gueddari B, Boukhis J. Carcinoma of the nasopharynx. Clinical aspects, indication and results of esternal radiotherapy and brachytherapy. State of the art in 2001. Cancer Radiother 2001; 5: S1189-S194
7. Glynne-Jones RG, Anand AK, Young TE, Berry RJ. Metastatic adenocarcinoma in the cervical nodes from occult primary: a conservative approach to the role of radiotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 289-94
8. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 2000; 47: 143-7
9. Bathia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG. Hormone receptor studies in axillary metastases from occult breast cancer. Cancer 1987; 59: 1170-2
10. Ellebroek N. Treatment of patients with isolated axillary metastases without evidence of primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461
11. Merson M, Andeola S, Galimbertir V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary nodal metastases without evidence of primary tumour. Cancer 1992; 70: 504-8.
12. Henry-Tillman RS, Harms SE, Westbrook KC, Korounian S, Klimberg VS. Role of breast magnetic resonance imaging in determining as a source of unknown metastatic lymphadenopathy. Am J Surg 1999; 496-500.
13. Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation in occult breast cancer. Ann Surg Oncol 2000; 7: 411-15.
14. JO, Muto MG, Welch WR et al. Molecular evidence for multifiocal papillary serous carcinoma of the peritoneum in patients with germ-line BCA 1 mutations. J Natl Cancer Inst 1998; 90: 841
15. Yann LT, Winckler CF, Janckila AJ, Li CY, Lam KW. Prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin. Cancer 1993; 51: 283-7.
16. Greco FA, Vangman WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Int Med 1996; 104: 547-53.
17. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese J.-L. Classification and regression tree of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403-10
18. Hainsworth JD, Greco FA. Poorly differentiated carcinoma and poorly differentiated tumour of unknown primary tumor site. Sem Oncol 1993; 20: 279-86.
19. Hales SA, Gatter KC, Hereyt A, Mason DY. Value of immunocytochemistry in differentiating hight-grade lymphoma from the other anaplastic tumours. A study of anaplastic tumours from 1940 to 1960. Leuk Lymphoma 1989; 1: 59
20. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998; 124: 1063-70
21. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discrimating primary from metastatic adenocarcinoma. Europen J Cancer 2002; 38: 758-63.
22. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
23. Ruddon RW, Norton SE. Use of biological markers in the diagnosis of cancers of unknown primary tumors. Sem Oncol 1993; 20: 251-60.
24. Pavlidis N, Kalef-Ezra J, Briassoulis E et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol 1994; 22: 162-7.
25. Milovic M, Popov I, Jelic S. Tumors markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit 2002; 8: MT1-6.
26. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma (serous) of Mullerian type: a subgroup of women presenting with peritoneal carcinomatous. Int J Gynecol Cancer 1994; 4: 43-51.
27. Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE. Two sequential studies from primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin/doxorubicin/cyclophosphamide or paclitaxel/cisplatin. Gynecol Oncol 1997; 67: 141
28. Karsell PR, Sheedy PF, O'Connell MJ. Computerized tomography search of cancer of unknow origin. JAMA 1982; 248: 340
29. McMillan JH, Levine E, Stephens Rh. Computed tomography in the evaluation of metastatic from an unknown primary site. Radiology 1982; 143: 143
30. Schorn C, Fischer U, Luftner-Naget S, westerhof JP, Grabbe E. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999; 9: 470-3.
31. Van der Gaast A, Verweij J, Plantings AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995; 13: 1720-25
32. Rades D, Kuhnel G, Wilfang I, Borner AR, Schmoll HJ, Knapp W. Localized disease in cancer of unknown primary (CUP). The role of positron emission (PET) for infdividual therapy management. Ann Oncol 2001; 12: 1605-19.
33. Lassen U, Dangaard G, Eigtved A, Damgaard K, Friterg L. 18F-FDG whole body positron emission tomography (PET) patients with unknown primary tumours (UTP). Eur J Cancer 1999; 35: 1076-82.
34. Koles AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg W. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82 : 1160-66.
35. Safa AA, Tran LM, Rege S et al. The role of positron emission tomography in occult priùary head and neck cancers. Cancer J Sci Am 1999; 5: 214-8
36. Greven KM, Keyes JW Jr, Williams DW 3rd, McGuirt WF Sr, Harkness BA, D'Agostino RB Jr, et al. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]-fluoro-2-deoxy-D-Glucose. Cancer 1999; 86: 114-18
37. Aassar OS, Fischbein J, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FOG-PET in locating primary tumors. Radiology 199; 210: 177-81.
38. Braams JW, Pruim J, Kole AC et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-15.
39. Schapira DV, Jarrett AR. The need to consider survival, outcome and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995; 155: 2050-4.
40. Levine MN, Drummond MF, Labelle RJ. Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown origin. CMAJ 1985; 133: 977-87
41. Le Chevalier T, Cvitkovic E, Caille P et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Med Intern 1988; 148: 2035-9
42. Mayordomo JL, Guerra JM, Guijarro C et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 1993; 79: 321-4
43. Dangaard G. Unknown primary tumours. Cancer Treat Rev 1994; 20: 119-47
44. Van de Vouw AJ, Janssen-Heijnen MLG, Coebergh JWW, Hillen HFF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38: 409-13.